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Mehta ZB, Fine N, Pullen TJ, Cane MC, Hu M, Chabosseau
P, Meur G, Velayos-Baeza A, Monaco AP, Marselli L, Mar-
chetti P, Rutter GA. Changes in the expression of the type 2
diabetes-associated gene VPS13C in the -cell are associated with
glucose intolerance in humans and mice. Am J Physiol Endocrinol
Metab 311: E488 –E507, 2016. First published June 21, 2016;
doi:10.1152/ajpendo.00074.2016.—Single nucleotide polymor-
phisms (SNPs) close to the VPS13C, C2CD4A and C2CD4B genes
on chromosome 15q are associated with impaired fasting glucose and
increased risk of type 2 diabetes. eQTL analysis revealed an associ-
ation between possession of risk (C) alleles at a previously implicated
causal SNP, rs7163757, and lowered VPS13C and C2CD4A levels in
islets from female (n  40, P  0.041) but not from male subjects.
Explored using promoter-reporter assays in -cells and other cell
lines, the risk variant at rs7163757 lowered enhancer activity. Mice
deleted for Vps13c selectively in the -cell were generated by cross-
ing animals bearing a floxed allele at exon 1 to mice expressing Cre
recombinase under Ins1 promoter control (Ins1Cre). Whereas
Vps13cfl/fl:Ins1Cre (Vps13cKO) mice displayed normal weight gain
compared with control littermates, deletion of Vps13c had little effect
on glucose tolerance. Pancreatic histology revealed no significant
change in -cell mass in KO mice vs. controls, and glucose-stimulated
insulin secretion from isolated islets was not altered in vitro between
control and Vps13cKO mice. However, a tendency was observed in
female null mice for lower insulin levels and -cell function
(HOMA-B) in vivo. Furthermore, glucose-stimulated increases in
intracellular free Ca2 were significantly increased in islets from
female KO mice, suggesting impaired Ca2 sensitivity of the secre-
tory machinery. The present data thus provide evidence for a limited
role for changes in VPS13C expression in conferring altered disease
risk at this locus, particularly in females, and suggest that C2CD4A
may also be involved.
VPS13C; C2CD4A; GWAS; type 2 diabetes; -cell
THE INCIDENCE OF TYPE 2 DIABETES (T2D) is now reaching
epidemic proportions across the globe, with deaths from the
disease reaching 5.1 million and disease complications costing
USD 548 billion in 2013 (30). These values are expected to
continue to increase, with predictions of a further 205 million
sufferers by 2035 (30). T2D is a complex metabolic disease
involving hyperglycemia and dyslipidemia, which together
conspire to cause serious secondary macro- and microvascular
complications including cardiovascular disease, retinopathy,
and neuropathy (11, 19). Although it is accepted that a loss of
an appropriate balance between functioning pancreatic -cell
mass and insulin action in peripheral tissues leads to abnormal
glucose homeostasis, the molecular basis of T2D onset and
progression is still poorly understood (31, 57).
While environmental factors such as increasingly sedentary
lifestyles and obesogenic diets have a substantial impact,
genetic susceptibility also plays a significant role in T2D risk
(57). Correspondingly, genome-wide association studies
(GWAS) have identified 90 loci harboring single nucleotide
polymorphisms (SNPs) that confer increased disease risk (13,
21, 23, 40, 57, 65, 86). Such studies have thus led to the
discovery of novel genes involved in T2D, such as T cell factor
7-like 2 (TCF7L2) (21) and SLC30A8 (58, 65). Of note, the
majority of the GWAS-identified loci affect insulin secretion
rather than action, further emphasising the likely role in disease
etiology of impaired insulin production.
The VPS13C/C2CD4A/C2CD4B locus was first associated
with T2D and glycemic traits in GWAS published in 2010 (6,
15, 22, 29, 60). Subsequent studies identified further SNPs at
this genomic location associated with poorer glycemic control
and T2D (12, 67, 78). The above studies encompassed a range
of distinct populations and age groups, thus providing confi-
dence that SNPs in this locus, acting via either nearby or more
remotely located genes, alter genetic susceptibility to T2D.
SNPs within the VPS13C/C2CD4A/B locus have been linked
to a range of glycemic parameters including higher fasting
proinsulin (29, 67), higher 2-h glucose and lower 2-h insulin
(60, 67), as well as increased fasting glucose (15, 22, 67) and
increased waist circumference (22). Two studies also associ-
ated risk alleles with lower glucose-stimulated insulin secretion
(GSIS) (6, 22, 67) and others with T2D (12, 67, 83). The “lead”
(GWAS index) SNP in this locus, rs7172432, is in LD with a
“functional” SNP, rs7163757, previously implicated by fine
mapping as the most strongly associated (P 3 1019) SNP
at this locus (61, 66). rs7163757 is located in an islet stretch
enhancer (50, 61, 66), again suggesting that the disease-
associated SNP acts on the expression of an effector gene(s) to
alter diabetes risk.
The first identified member of the highly conserved VPS13
(vacuolar protein sorting 13) family of proteins was Soi1 (or
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Vps13) in Saccharomyces cerevisiae, where it plays an impor-
tant role in membrane protein trafficking between the trans-
Golgi network (TGN) and the prevacuolar compartment (7).
Specifically, Vps13 is involved in trafficking the protease
Kex2p, a protein involved in intracellular insulin processing
after overexpression of the latter in yeast (85). Subsequently, a
role for this protein was demonstrated in prospore formation in
S. cerevisiae through the regulation of phosphatidylinositol
4-phosphate [PI(4)P] generation and membrane-bending activ-
ity (48, 49).
In both humans and mice, the VPS13 family comprises four
members (A–D), with VPS13A and VPS13C showing the most
similarity to the yeast homolog (73). All four proteins are large
and have potential functions in membrane protein trafficking,
Golgi structure, and/or phosphatidylinositol metabolism (37,
47, 53, 62, 63, 73). Mutations in VPS13A and VPS13B cause
the genetic diseases chorea-acanthocytosis (ChAc) and Cohen
syndrome, respectively (32, 53, 71), and a loss of VPS13C
function has recently been linked to early-onset Parkinson’s
disease (35).
VPS13C is ubiquitously expressed in mammals, with par-
ticularly high levels in pancreatic islets and -cells (60, 67).
The observations above have thus led us to hypothesize that
VPS13C may play a role in the intracellular trafficking of
insulin or other aspects of pancreatic -cell function. To
explore this possibility, we first determined the relationship
between the possession of T2D risk alleles in humans and the
expression of VPS13C, C2CD4A (C2 calcium-dependent do-
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Fig. 1. eQTL (expression quantitative trait loci) analysis. Expression of VPS13C (A–C), C2CD4A (D–F), and C2CD4B (G–I) was quantified relative to ACTB
in 53 human donor islet samples and compared with the genotype at rs7163757. 	CT is plotted against genotype for all samples (A, D, G; n 53) or just samples
from male (B, E, H; n  13) or female (C, F, I; n  40) donors, along with the mean and standard error. Since higher 	CT corresponds to lower expression,
possession of the risk allele (C) is significantly associated with lower VPS13C expression in samples from female donors (P  0.041).
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main 4A), and C2CD4B in human islets. Subsequently, we
developed mice inactivated for Vps13c highly selectively in
the -cell by using the recently developed Ins1Cre deleter
strain (33, 69). The latter is a knock-in model that avoids the
complications associated with earlier insulin 2 promoter-de-
pendent Cre’s including recombination in the brain (77) and
coexpression of human growth hormone (8). This approach
reveals roles for Vps13c in the control of whole body glucose
homeostasis, insulin secretion in vivo, and glucose-induced
Ca2 signal generation in the -cell but suggests that C2CD4A
may also contribute to disease risk.
MATERIALS AND METHODS
Materials. All general chemicals and materials were purchased
from Sigma (Dorset, UK) or Fisher Scientific (Loughborough, UK)
unless otherwise indicated.
Generation of VPS13C antibodies. A custom polyclonal antibody
against human VPS13C, based on amino acids 1582–1882 of human
VPS13C isoform 2A (UniProtKB Q709C8-1; 84% identities, 92%
positives with mouse VPS13C protein Q8BX70-1, positions 1580–
1879) was raised in rabbits, as recently described (84).
Ethics. All in vivo procedures were conducted in accordance with
UK Home Office regulations [Animals (Scientific Procedures) Act of
1986, Home Office Project License number PPL 70/7349, Dr. Isabelle
Leclerc]. Procedures were performed at the Central Biomedical Ser-
vice at Imperial College, London. Isolation of islets from multiorgan
donors was approved by the local ethics committee at the University
of Pisa. Human pancreata were collected from brain-dead organ
donors after informed consent was obtained in writing from family
members. Use of human islets at Imperial College was approved by
the local NRES Committee, Fulham; REC reference 07/H0711/114.
Expression quantitative trait loci analysis. Human islet DNA
samples obtained from 53 donors (see Supplementary Table 1 online
for clinical characteristics), using the DNeasy Blood & Tissue Kit
(QIAGEN, Hilden, Germany) as previously described (51), were
genotyped for SNPs rs4502156, rs7172432, and rs7163757. The
rs7172432 locus was amplified by semi-nested PCR using primers
TAG GTA TCT TGG AGC TGA GG and CCA CAC TTC ACA
GAA TCA GG for the first round amplification and then CAG GTC
AAG TGA GCA CTT GC and CCA CAC TTC ACA GAA TCA GG
for the second round. The amplicons were then digested with SspI and
genotyped based on the resulting restriction fragment length polymor-
phism.
Islet RNA was isolated from hand-picked islets as described (39),
using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems,
Foster City, CA), according to the procedure recommended by the
manufacturer for RNA extraction from cell pellets and was accord-
ingly treated with DNase to remove the contamination with genomic
DNA. Reverse transcription to cDNA was performed using a High
Capacity cDNA Reverse Transcription Kit (Themofisher). The
rs4502156 and rs7163757 SNPs were genotyped by qPCR using a
commercial TaqMan assay (Applied Biosystems). VPS13C,
C2CD4A, and C2CD4B mRNA abundances were measured relative
to ACTB in corresponding RNA samples by qRT-PCR using com-
mercial TaqMan assays (Applied Biosystems) and the 	CT method.
As a quality control step, samples with 	CT standard deviation 
 0.2
were excluded from the analysis. The association between VPS13C
expression and genotype was tested using an ANCOVA model,
controlling for age, sex, and BMI and implemented in R (52). The
association of genotype with C2CD4A and C2CD4B was analyzed
in the same manner. Linkage disequilibrium (LD) values for SNPs
in the Tuscan population used here were obtained at: http://
www.1000genomes.org/faq/which-populations-are-part-your-study.
Luciferase construct cloning and assay. To assess whether variants
at rs7163757 might cause changes in the expression of nearby genes,
two reporter constructs were generated. A 1.3-kb fragment of the
genomic region flanking the SNP was amplified by PCR from a
heterozygous donor by using Phusion High Fidelity DNA Polymerase
(Thermo Scientific, Paisley, UK). The PCR product was subsequently
cloned into CR™8/GW/TOPO (Thermofisher, Paisley, UK) accord-
ing to the manufacturer’s instructions. Plasmid DNA from clones was
purified using a GenElute Plasmid Miniprep Kit (Sigma, Dorset, UK)
and sent for sequencing to identify clones containing one of each
allele. DNA fragments were then shuttled into the minimal promoter
(DNA sequence: TAG AGG GTA TAT AAT GGA AGC TCG ACT
TCC AG, containing a TATA box promoter element)-driven lu-
ciferase vector GL4.23-GW vector (76) using the Gateway LR Clo-
nase II Enzyme Mix (Invitrogen, Paisley, UK). pGL4.23-GW is
modified from pGL4.32 (Promega) with Gateway technology (Ther-
mofisher) and has previously been used successfully for the analysis
of enhancer activity (20).
The sequence and orientation of the insert was checked by restric-
tion enzyme digest, and subsequently a QIAGEN Plasmid Maxi Kit
(QIAGEN, Manchester, UK) was used to purify transfection grade
DNA. HEK293, MIN6 (44), 1.1B4 (41), and EndoC-H1 (54) cells
were transfected using Lipofectamine 2000 (Invitrogen, Paisley, UK)
in 48-well plates using 250 ng of each reporter construct and 1 ng of
Renilla control vector. Each condition was repeated in six separate
wells. Dual-Luciferase Reporter Assay (Promega, Southampton, UK)
was used to measure Luciferase normalized against Renilla. All
experiments were done in triplicate. The following cloning primers
were used: CCA ACA AAT AGT AAG CAT TAT TAC C
(rs7163757, forward) and CAA ATA GTT GTA GAT ATG TGG
CAT T (rs7163757, reverse).
Mouse generation, housing, and genotyping. Generation of
heterozygous embryos on a C57/BL6 background, carrying floxed
alleles of Vps13c was conducted by GenOway (France). Vps13cfl/fl
mice were crossed to mice expressing Cre recombinase under the
control of the Ins1 promoter (33, 69) to generate mice in which exon
1 of the Vps13c gene was selectively excised in pancreatic -cells.
Mice were born at the expected Mendelian ratios without any obvious
physical or behavioral defects. Mice were housed two to five per cage
in a pathogen-free facility under a 12:12-h light-dark cycle and had ad
libitum access to water and standard mouse chow diet (Research Diet,
New Brunswick, NJ). High-fat diet (HFD, 60% wt/wt fat content;
Research Diet) was introduced at 4 wk of age.
Genotyping was performed from ear biopsies using PCR. Knockout
of Vps13c from pancreatic islets was assessed using both qPCR and
immunoblotting, as described below. Mice were weighed weekly
from 5 wk of age, and random, fed glycemia was tested fortnightly in
the afternoon.
Intraperitoneal and oral glucose tolerance tests. Mice were fasted
for 15–16 h overnight prior to intraperitoneal (IPGTT) and oral
Fig. 2. Comparison of promoter/enhancer activities of variants at rs7163757 in
the VPS13C locus. Luciferase reporter assay performed in 4 cell lines
(HEK293, MIN6, 1.1B4, and EndoC-H1). The risk single nucleotide poly-
morphisms (SNP) caused a significant reduction in enhancer activity in
HEK293, MIN6, and 1.1B4 (*P  0.05, **P  0.01 calculated using ratio
paired Student’s t-tests). Error bars represent SE from either 3 (HEK293 and
MIN6) or 4 (1.1B4 and EndoC-H1) independent experiments. P 0.1 for the
effect of the risk allele in EndoC-H1 cells.
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Fig. 3. Generation of VPS13Cfl/fl::Ins1.Cre/ (Vps13cKO) mice. A: LoxP sites were inserted on either side of exon 1 to enable Cre-mediated inactivation of
the Vps13c gene in pancreatic -cells after breeding to Ins1.Cre mice. The resultant colony consisted of VPS13C-null mice (KO, Vps13cKO) and control mice
(Ctrl) at the expected 50:50 ratio. B and C: islets were isolated from 2–3 male (B) and 3 female (C) Ctrl and KO mice for (i) immunoblotting or (ii) qPCR analysis.
Both 	CT (relative to cyclophilin A) and log2-transformed fold changes, normalized to control mice, are shown. Error bars represent standard deviation in (ii)
top and 95% confidence intervals in (ii) bottom. *P 0.05, **P 0.01 analyzed with 2-way ANOVA with Sidak’s multiple corrections. D–G: changes in weight
(D and E) and random-fed glycemia (F and G) over time for Ctrl (black) and KO (dashed) mice fed regular chow (RC, circles or squares) or high-fat diet (HFD,
triangles). Inset: area under the curve (AUC) analysis for female mice on HFD, assessed for significance using an unpaired Student’s t-test; n  11–15 mice,
as indicated.
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glucose tolerance tests (OGTT) with free access to water. Blood
samples were taken for glycemia measurement via venesection of the
tail vein. Glycemia was measured using an Accu-Chek glucometer
(Roche Diabetes Care, UK) and appropriate measurement strips.
Fasting glycemia was first measured (time 0), and then glucose was
administered via ip injection (1 g/kg body wt) or oral gavage (1.5 g/kg
body wt). Glycemia measurements were then taken by injection at 15,
30, 45, 60, 90, and 120 min.
Measurement of plasma insulin and proinsulin. Mice were fasted
overnight with free access to water. A fasting (time 0) blood sample
(50 l) was collected from the tail vein into a lithium-heparin-lined
Microvette (Starstedt, Leicester, UK) before administering of glucose
(3 g/kg body wt) via ip injection. Blood samples were then collected
at 15 and 30 min after injection. Glycemia was also measured at these
time points. Plasma was collected by centrifuging samples at 2,000 g
for 10 min at 4°C. Plasma insulin was measured using an ultrasensi-
tive mouse insulin ELISA (Crystal Chem, IL). For random-fed insu-
lin/proinsulin ratio measurements, a blood sample was collected into
a lithium-heparin-lined Microvette from the tail vein and the aorta
immediately after culling via cervical dislocation. Samples were kept
on ice at all times to prevent degradation of proinsulin, and plasma
was collected as described above. Insulin was measured as described
Fig. 4. Glucose tolerance in male
Vps13cKO mice. A–H: intraperitoneal glu-
cose tolerance (1 g/kg body wt) was mea-
sured in Ctrl (solid black line) and KO
(dashed line) male littermates fed either RC
(A, C, E, G) or HFD (B, D, F, H). IPGTTs
were conducted at 8 (A, B), 12 (C, D), 16 (E,
F), and 20 (G, H) wk. Inset: AUC. Numbers
of animals (n) for each experiment are given
in AUC bars. *P  0.05, **P  0.01, 2-way
ANOVA with Fisher’s LSD post hoc test
(main graphs) or unpaired Student’s t-test
(AUC, insets).
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above, and proinsulin was measured using a Rat/Mouse Proinsulin
ELISA (Mercodia, Uppsala, Sweden).
Homeostatic model assessment analysis. Homeostatic model as-
sessment analysis (HOMA2)-%S and-%B (36) were calculated using
fasting glycemia and plasma insulin measurements, with the HOMA
Calculator, as described (https://www.dtu.ox.ac.uk/homacalculator/
download.php).
Isolation of islets and assay of insulin secretion. Mice were culled
by cervical dislocation. Islets were isolated after pancreatic distension
with collagenase essentially as previously described (55). Islets were
allowed to recover from digestion for 24 h (RC-fed mice) or 48 h
(HFD-fed mice) in RPMI medium (GIBCO) supplemented with 10%
(vol/vol) fetal bovine serum, 1% (wt/vol) penicillin, 1% (wt/vol)
streptomycin, 11.1 mM glucose, and 2 mM L-glutamine. Insulin
secretion was measured from duplicate batches of 10 islets incubated
in 0.5 ml of Krebs-Ringer medium [130 mM NaCl, 3.6 mM KCl, 1.5
mM CaCl2, 0.5 mM MgSO4, 0.5 mM NaH2PO4, 2 mM NaHCO3, 10
mM HEPES, and 0.1% (wt/vol) BSA, pH 7.4] containing 3 or
16.7 mM glucose or 20 mM KCl and 3 mM glucose as indicated, and
shaking at 37°C for 30 min. Total insulin was extracted into 0.5 ml of
acidified ethanol [75% (vol/vol) ethanol, 1.5% (vol/vol) 1 M HCl and
0.1% (vol/vol) Triton X-100]. For continuous measurements of secre-
tion, insulin samples from 50 perifused islets were collected using a
custom-built device and a perifusion rate of 500 l/min at 37°C as
Fig. 5. Glucose tolerance in female
Vps13cKO mice. A–H: intraperitoneal glu-
cose tolerance (1 g/kg body wt) was mea-
sured in Ctrl (solid black line) and KO (dot-
ted line) female littermates fed RC (A, C, E,
G) or HFD (B, D, F, H). IPGTTs were
conducted at 8 (A, B), 12 (C, D), 16 (E, F),
and 20 (G, H) wk. Inset: AUC. Numbers of
animals (n) for each experiment are given in
the AUC bars. *P  0.05, 2-way ANOVA
with Fisher’s LSD post hoc test (main
graphs) or unpaired Student’s t-test (AUC,
insets).
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described previously (10). Secreted and total insulin concentrations
were measured using a homogeneous time-resolved fluorescence-
based (HTRF) insulin assay (CisBio, Codolet, France) in a
PHERAstar reader (BMG Labtech), according to the manufacturer’s
instructions.
Determination of - and -cell mass. Isolated pancreata were fixed
in 10% (vol/vol) formalin overnight at 4°C and embedded in paraffin
wax. Sections (5 m) were cut and fixed onto Superfrost slides. For
staining, five sections per mouse, 25 m apart, were incubated in
Histochoice Clearing Agent and then submerged consecutively in 100,
95, and 70% ethanol to remove the wax. Following washes with
water, sections were permeabilized by boiling in a citrate-based
antigen unmasking solution (Vector Labs, Peterborough, UK), washed
with PBS, and then incubated in PBS-Triton X-100 [PBST, 0.1%
(vol/vol)] containing 2% (wt/vol) BSA and 2% (vol/vol) goat and
donkey serum for 2 h at room temperature. Sections were then
incubated in a humidified chamber at 4°C overnight with guinea pig
anti-insulin (1:200; Dako, Ely, UK) and mouse anti-glucagon (1:
1,000; Sigma, Dorset, UK). After washing three times in PBST
[0.25% (vol/vol)] containing 0.25% (wt/vol) BSA, sections were
incubated with Alexa fluor 488 and 568-conjugated secondary anti-
bodies (1:1,000; Invitrogen, Paisley, UK) for 2 h at room temperature
in the dark. Sections were then mounted using Vectashield antifade
mounting medium containing DAPI (Vector Labs). Slices were im-
aged in the Imperial College facility for imaging by light microscopy
(FILM) (http://www3.imperial.ac.uk/imagingfacility), using a Zeiss
Axio Observer inverted widefield microscope with LED illumination.
Images were captured with a Hamamatsu Flash 4.0 fast camera
controlled by Zen software (Zeiss, Cambridge, UK). Image analysis
was conducted using ImageJ software (1) and an in-house macro as
described under SUPPLEMENTARY METHODS (see online).
Quantitative real-time PCR analysis. Total RNA was extracted
from 50–200 islets isolated from three control and three Vps13cKO
mice (for both males and females) using TRIzol (ThermoFisher
Scientific) according to the manufacturer’s instructions. RNA (100
ng) was reverse transcribed to produce cDNA by using the High
Capacity Reverse Transcription Kit (Life Technologies, Paisley, UK)
with random primers. qPCR was conducted using SYBER Green (life
Technologies, Paisley, UK) on an ABI-Fast Prism 7500 machine and
primers specific to murine Vps13c, C2cd4a, C2cd4b, or cyclophilin A.
Primers were designed using Primer Express 3.0 (Applied Biosys-
tems, CA), and sequences used were: Vps13c forward CAC AAG
CAT TGA AGA TAG AAG CAA AA, reverse AGT GAT GGC ACA
ATG TCT TGT TG; C2cd4a forward CGG GTT GGA AAA CCA
TCT GA, reverse GTC TGA ACC CTG TGA TCC TGT TC; C2cd4b
forward ACG TCA CCT GCT TCG TTC CT, reverse CAC GAG
CGT CTT TTC TTC TTC A; cyclophilin A forward TAT CTG CAC
TGC CAA GAC TG A, reverse CCA CAA TGC TCA TGC CTT CTT
TCA. Whereas the VPS13C and C2CD4B primers spanned exon/exon
junctions, the C2CD4A primers spanned intron 1.
Western immunoblotting. Total protein was extracted from 50–500
islets isolated from two or three control or -cell-specific VPS13C
knockout (Vps13cKO) mice (males and females) in ice-cold RIPA
buffer [1% (vol/vol) Triton X-100, 1% (wt/vol) sodium deoxycholate,
0.1% (wt/vol) SDS, 0.15 M NaCl, 50 mM Tris, pH 8.0] containing a
2 concentration of Complete, EDTA-free protease inhibitor cocktail
(Roche, Burgess Hill, UK). The samples were incubated in RIPA on
ice for 10 min and then freeze-thawed twice to ensure release of
proteins. Samples were clarified by centrifuging at 16,000 g for 10
min at 4°C, and then total protein content was quantified using a BCA
protein assay kit (Pierce, ThermoScientific). Total protein (5 g) was
added to SDS sample buffer [0.5 M Tris·HCl, pH 6.8, 2% (wt/vol)
SDS, 5% (wt/vol) glycerol, 0.6 M DTT, and 0.2 mg bromophenol
blue] and incubated at room temperature for 30 min. Samples were
then electrophoresed on a 4–10% discontinuous gradient gel along-
side a HiMark Protein Standard (Novex; ThermoScientific) and trans-
ferred onto a nitrocellulose membrane overnight. Membranes were
blocked with 5% milk and incubated with primary antibodies (rabbit
anti-VPS13C, 1:2,000, described above, or goat anti-EEA1, Santa
Cruz, TX, 1:2,000) overnight with agitation at 4°C. Membranes were
then washed three times in PBS-Tween 20 (0.2% vol/vol) and incu-
bated with horseradish peroxidase-conjugated antibodies for 1 h at
room temperature. Following three washes in PBS-Tween 20, proteins
were visualized with ECL reagent and X-ray film (Amersham, GE
Healthcare Life Sciences).
Confocal immunocytochemistry. Human islets were dissociated by
10-min incubation in Hanks’-based enzyme-free cell dissociation
buffer (GIBCO, Invitrogen) and gentle pipetting to generate small
clusters of cells. Dissociated cells were plated onto 13/24-mm sterile
coverslips and allowed to recover for 1–2 days. Cells were fixed in 4%
paraformaldehyde and permeabilized in 0.1% Triton X-100. Primary
cells were blocked in 10% fetal calf serum and subsequently incu-
bated overnight with VPS13C 15-E antibody (Santa Cruz sc-104751,
1:50) with or without anti-insulin antibody (1:200; Dako, Ely, UK)
followed by incubations with Alexa 488 and Alexa 568-conjugated
secondary antibodies in sequential order. Coverslips were mounted
using VectaShield with DAPI and imaged as described elsewhere
(42). Samples were illuminated using steady-state 488- and 560-nm
laser lines, and emission was collected through ET535/30 and
ET620/60 emission filters (Chroma). Images were captured using a
Hamamatsu EM CCD digital camera controlled by an Improvision/
Nokigawa spinning disc system running Volocit (PerkinElmer, MA)
software.
Confocal Ca2 imaging. Islets were isolated as described above.
Simultaneous imaging of Ca2 of individual cells was performed by
spinning disc confocal microscopy after loading intact islets with Fluo
2-AM (Cambridge Bioscience, Cambridge, UK). Images were cap-
tured with a Zeiss Axiovert 200M microscope fitted with a 10
0.3–0.5 NA, EC Plan Neofluar, Zeiss objective and a 1.5 Optivar
attached to a Nokigawa spinning disc confocal head, as described
(27). The microscope was controlled using Volocity software. Islets
were continuously perifused in Krebs-Ringer buffer containing 3 mM
glucose, equilibrated with 95% O2-5% CO2 at 34–36°C. Islets were
stimulated at 210 s and 1,300 s by perifusion with Krebs-Ringer
Fig. 6. Oral glucose tolerance in
Vps13cKO and control mice. A and B: oral
glucose tolerance (1.5 g/kg body wt) was
measured in Ctrl (solid black line) and KO
[dashed (male) or dotted (female) lines] lit-
termates fed RC. OGTTs were conducted at
ages indicated. Inset: AUC; n, numbers for
each experiment are given in AUC bars.
*P  0.05, 2-way ANOVA with Fisher’s
LSD post hoc test.
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Fig. 7. Effect of Vps13C deletion on glucose-stimulated insulin secretion (GSIS) in vivo. A–D: plasma insulin concentration was measured following
intraperitoneal administration of glucose (3 g/kg body wt) in Ctrl (solid black line) and KO [dashed (males) or dotted lines (females)] littermates. Blood was
sampled for insulin measurements when mice were 21 or 19 wk old (RC or HFD, respectively). Inset, top: respective glycemia measurements. Inset, bottom: AUC
calculated from the main graph, measuring total released plasma insulin; n  6–9 mice per genotype, as detailed in the key. E–H: homeostatic model assessment
analysis (HOMA2)-%B (E and G) and -%S (F and H) analysis using fasting glycemia values and corresponding plasma insulin concentrations, respectively.
**P  0.01, unpaired Student’s t-test with Welch’s correction (E–H).
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supplemented with up to 16.7 mM glucose or 20 mM KCl as
indicated. Offline processing and analysis were conducted using
ImageJ software (1) and an in-house macro as described under
SUPPLEMENTARY METHODS.
Statistics. Data were analyzed using Microsoft Excel, GraphPad
PRISM 6.0, and R. Significance was tested using an unpaired Stu-
dent’s two-tailed t-test with appropriate posttests for multiple com-
parisons, or two-way ANOVA, as indicated. P 0.05 was considered
significant, and errors signify means  SE unless otherwise stated.
Figures were constructed using Adobe Illustrator.
RESULTS
eQTL analysis. GWAS studies have implicated SNPs close
to VPS13C, C2CD4A, and C2CD4B in altered T2D suscepti-
bility. We tested the association between genotype at one of the
previously identified SNPs rs4502156 and the likely causal
SNP rs7163757 (61, 66) (r2  0.939, D=  0.979 with
rs4502156) and VPS13C expression in human islet samples
from 53 donors. Initial analysis for rs4502156 and rs7163757
including all samples showed no significant association. Inter-
action plots indicated a possible interaction between sex and
genotype, which was tested by including the interaction term in
the ANCOVA model (see MATERIALS AND METHODS). This was
found to be significant (P  0.015, n  53), so data were
stratified by sex, and subsequently males and females were
analyzed separately (Fig. 1, A–C). Analysis of females re-
vealed a significant association between possession of the risk
allele (C) at rs7163757 and lowered VPS13C expression (P 
0.041, n  40; Fig. 1C). A similar sex interaction (P  0.016,
n  53) was also observed for rs4502156, and likewise a
significant association was detected between genotype at this
Fig. 8. Effect of Vps13c deletion on GSIS in
vitro. A–D: insulin secretion from isolated
islets from KO and Ctrl mice over 20 wk old
maintained on RC (A and C) or HFD (B and
D) was assessed by incubating 10 size-
matched islets in Krebs-Ringer solution con-
taining 3 mM glucose (3 Glu), 16.7 mM
glucose (16.7 Glu), or 20 mM KCl for 30
min and measuring the amount of insulin
secreted (see MATERIALS AND METHODS). Is-
lets were lysed to measure total insulin;
results are presented as %total insulin. E:
insulin secretion from islets continuously
perifused with Krebs-Ringer solution con-
taining 3 mM glucose and then stimulated
with 16.7 mM glucose; n  3–5 mice per
genotype, as indicated. *P  0.05, **P 
0.01, ***P  0.001, ****P  0.0001,
2-way ANOVA with Sidak or Tukey’s post
hoc test where appropriate.
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locus and expression of VPS13C in females (P  0.043, n 
40). An association was also detected between rs4502156 (not
shown), as well as rs7163757 (P  0.011, n  40; Fig. 1,
D–F), with C2CD4A mRNA levels in female donors but not
with C2CD4B (Fig. 1, G–I). Subsequent functional studies in
the present report focussed upon VPS13C.
Impact of risk alleles on enhancer activity assessed by
reporter luciferase assay. To determine whether and how the
possession of risk alleles at the VPS13C locus might affect the
expression of nearby or remotely located genes, we used
reporter-luciferase assays in non--cells (HEK293) and in
-cell lines from mice (MIN6) and humans (1.1B4 and
EndoCH1). As shown in Fig. 2, inclusion of the risk (C) allele
at the previously implicated causal SNP rs7163757 signifi-
cantly lowered the enhancer/promoter activity of reporter con-
structs bearing this variant vs. the presence of the protective
(T) allele in HEK293, MIN6, and 1.1B4 cells. A similar
tendency (P  0.1) was observed in EndoCH1 cells (Fig. 2).
These data are thus consistent with an enhancer function for
this region, whose activity is lowered in carriers of risk alleles.
Impact of -cell-selective deletion of Vps13c on body mass
and fasting glycemia. The observations above suggested that
risk variants at the VPS13C locus may decrease the expression
of nearby genes. To explore the potential impact of lowered
VPS13C levels on insulin secretion, deletion of exon 1 (Fig.
3A) of the Vps13c gene was achieved throughout the pancre-
atic -cell compartment in C57BL/6 mice from E11.5 using
the highly selective Ins1Cre deleter strain (69). As shown in
Fig. 3, B and C, VPS13C was barely detected in islets isolated
from Vps13cKO mice (Fig. 3B and Ci) and levels of Vps13c
mRNA were significantly reduced (Fig. 3, Bii and Cii) by

80%. These findings are fully consistent with efficient
(
94%) and exclusive (69) recombination in -cells, which
comprise 60–80% of the rodent islet (16), given that Vps13c
mRNA is about twofold more abundant in - than in -cells
(5), which comprise the majority of the islet non--cells.
Expression of C2cd4a and C2cd4b in islets was variable
between mice but was unaffected by Vps13c deletion. Changes
in body weight gain (Fig. 3, D and E) and random-fed glycemia
(Fig. 3, F and G) over time were not different between control
(Ctrl) and Vps13cKO (KO) mice irrespective of sex or diet
[regular chow (RC) vs. high-fat diet (HFD); see MATERIALS AND
METHODS for details].
Vps13cKO mice display age-dependent abnormalities in
glucose tolerance. Examined in male mice, intraperitoneal
glucose tolerance (IPGTT) was not different between control
and Vps13cKO animals up to the age of 16 wk, whereas
Vps13cKO mice became glucose intolerant at 20 wk of age
(Fig. 4, A, C, E, G). Although glucose tolerance was lower at
all ages examined compared with animals maintained on RC,
no differences were observed between control and
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Fig. 9. -Cell mass in Vps13cKO mice. A and C: representative images from
pancreatic slices from female (A) and male (B) Ctrl and KO mice (20–23 wk
of age) fed a RC diet. Slices were stained with antibodies against insulin
(green) and glucagon (red). Nuclei were stained with DAPI; scale bar repre-
sents 50 m. B and D: percentage of - (i) and -cell (ii) surface area,
normalized to whole pancreas surface area; (iii): /-cell ratio. Data are from
n  3 Ctrl and 3 KO females and 3 Ctrl and 5 KO males. No significant
differences between genotypes were detected.
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Vps13cKO males maintained for up to 16 wk (i.e., 20 wk old)
on a HFD (Fig. 4, B, D, F, H).
By contrast, when maintained on RC, female mice (Fig. 5)
displayed abnormal IPGTT at 12 wk of age (Fig. 5C). This
resolved at 16 wk but was again apparent at 20 wk (Fig. 5G).
Consistent with observations in males (Fig. 4), female
Vps13cKO mice fed HFD similarly failed to show abnormal-
ities in IPGTT up to 20 wk of age (Fig. 5, B, D, F, H).
To test a possible role for Vps13c in responses to incretin
hormones, we next performed oral glucose tolerance tests
(OGTT) in RC-fed mice. No genotype-dependent differences
were apparent in males (Fig. 6A) or females (Fig. 6B) exam-
ined at 22–24 wk.
Examined in mice aged 19–21 wk, glucose-induced excur-
sions in plasma insulin were not different between
Vps13cKO and control male and female mice (Fig. 7, A–D).
Likewise, by analyzing fasting glucose and insulin levels, we
observed no indication of a change in steady-state -cell
function (36) as assessed using homeostatic model assessment
(HOMA2-%B; Fig. 7E), nor insulin in insulin sensitivity
(HOMA2-%S; Fig. 7F) in males maintained on either RC or
HFD. By contrast, a tendency toward a lower HOMA2-%B
value (Fig. 7G), accompanied by a significant increase in
HOMA2-%S, was apparent in female Vps13cKO mice vs.
controls fed on RC, whereas these differences were not ob-
served on HFD (Fig. 7, G and H).
Impact of Vps13c deletion on glucose- and KCl-stimulated
insulin secretion in vitro. Impairments in glucose tolerance and
a tendency toward impaired -cell function apparent in vivo in
female Vps13cKO mice might reflect abnormal glucose- or
depolarization-dependent insulin secretion from -cells. To
investigate this, we studied insulin release from batches of
islets from mice 20–23 wk old, as shown in Fig. 8. Interest-
ingly, both glucose (16.7 mM) and KCl (20 mM) -stimulated
secretion tended to increase in Vps13cKO vs. control islets
from males fed either RC (Fig. 8A) or HFD (Fig. 8B). Whereas
a similar tendency was also apparent for islets from females
maintained on a HFD (Fig. 8D), those from female
Vps13cKO mice fed RC showed no change in insulin secre-
tion vs. controls (Fig. 8C) when stimulated with 20 mM KCl.
No differences between HFD-fed control and Vps13cKO
mice were seen when the same experiment was conducted
under perifusion (Fig. 8E).
-Cell mass is not changed after Vps13c deletion. One
explanation for the differences in glucose tolerance and insulin
secretion seen in Vps13cKO mice may be an alteration in
-cell mass. To establish whether this was the case, we
conducted immunohistochemical analyses on pancreatic sec-
tions from Vps13cKO and control mice fed RC and aged over
20 wk. Using antibodies against either insulin or glucagon, we
observed no differences in %- or -cell surface normalized
pancreatic surface (Fig. 9, A and B, females; C and D, males).
Sex-specific effects of Vps13c deletion on intracellular Ca2
dynamics. Alterations in glucose tolerance and tendency to-
ward impaired insulin secretion, which were apparent in vivo,
may reflect altered signal generation by glucose. We next used
the fluorescent intracellular probe Fluo 2 (27) to monitor
intracellular free Ca2 dynamics in -cells in situ within the
intact islet (Figs. 10 and 11). Under the conditions used,
glucose-induced changes in free Ca2 were largely restricted to
the -cell population (10, 27). No genotype-dependent differ-
ences in the peaks of the Ca2 response to either high glucose
or KCl were apparent in islets from male mice (Fig. 10),
although islets from male Vps13cKO mice fed RC did dis-
play a significantly delayed response to high glucose stimula-
tion (Fig. 10A, ii and v). Increases in free Ca2 in islets from
female mice were respectively augmented (Fig. 11A, i and vi)
and reduced (Fig. 11B, i and vi) in high-glucose-stimulated
islets from Vps13cKO animals fed RC or HFD. A similar
trend was seen after depolarization with KCl (Figs. 11A, i and
viii, and B, i, iv, and viii). As was the case for male mice, the
response to glucose in islets from HFD-fed female mice was
slightly delayed, with those from RC mice showing no signif-
icant difference in the time of the glucose peak (Fig. 11A, i and
v, and B, i and v).
Subcellular localization of VPS13C in human -cells. To
determine whether VPS13C might conceivably affect the prop-
erties (i.e., “fusogenecity”), or the distribution of secretory
granules, we explored the localization of the protein with
single human -cells by confocal immunocytochemistry (Fig.
12). Close colocalization was observed between insulin and
VPS13C-labeled structures, indicative of the presence of the
latter on the limiting membrane of insulin-containing dense
core granules.
DISCUSSION
Previous studies (17) have revealed that VPS13C expression
in human islets is associated with HbA1c levels by massive
parallel sequencing (RNA-seq) and microarray analysis at both
nominal and permutation P values (P  0.05), with lower
mRNA levels observed in T2D subjects. We extend these
findings here by showing that VPS13C mRNA levels were
lower in carriers of risk alleles at rs4502156 and rs7163757 in
female, but not male subjects. We note that in the present study
a lower number of male vs. female samples may have limited
our power to detect changes in the former. However, and
arguing against this possibility, no tendency toward lowered
VPS13C or C2CD4A expression with the interrogated SNPs
Fig. 10. Effect of Vps13c deletion on calcium signaling in vitro in male mouse islets. Isolated islets from male mice (20–23 wk of age), maintained on RC (A)
or HFD (B) were loaded with Fluo 2 and incubated in Krebs-Ringer solution containing 3 mM glucose (3 mM Glu) for 45 min. Dye-loaded islets (3–7 per field
of view) were imaged on a spinning disk confocal microscope for 2 min in 3 mM glucose, as described in MATERIALS AND METHODS. A perifusion system was
used to allow subsequent imaging of the islets in 16.7 mM Glu for 18 min, followed by 20 mM KCl for 5 min. Individual traces from each islet were then averaged
to give one trace per islet, which was then pooled with the other islets. (i), mean free Ca2 (normalized to initial fluorescence; F/F0); (ii), inset from (i), mean
free Ca2 measured between 300 and 500 s, showing the effect of stimulation with 16.7 mM glucose; (iii), AUC analysis for high glucose stimulation; (iv), AUC
analysis for KCl stimulation; (v), time to maximum peak value from stimulation with glucose; (vi), maximum peak value (F/F0) from stimulation with glucose;
(vii), time to maximum peak value from stimulation with KCl; (viii), maximum peak value (F/F0) from stimulation with KCl; n  3–5 mice per genotype.
Number of islets used: n  male RC 31–38 islets from 3 mice; male HFD mice n  41–46 islets from 4 mice. *P  0.5, **P  0.01, ***P  0.001, unpaired
Student’s t-test.
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was observed in males: rather, the trend was toward increased
expression with risk alleles.
Using mouse genetics we provide evidence that VPS13C
plays a role in the control of pancreatic -cell function. It
should be emphasized that the impact of deleting this gene
selectively in the -cell was relatively mild and indeed was not
apparent in males until 20 wk of age. Evidence for deficiencies
in -cell function were, however, more apparent in females
from an earlier age, in line with the human eQTL data. These
included the transient appearance of glucose intolerance at 12
wk and its reemergence at 20 wk. Interestingly, the same
phenomenon is also observed in a monogenic form of diabetes
resulting from misexpression of the ZAC gene, termed tran-
sient neonatal diabetes mellitus (TNDM), and is apparent in
mouse models with this disease (albeit in younger animals than
observed here) (38). While the reasons for this transience are
not known either in TNDM or in the case of Vps13c deletion,
dynamic changes in the balance between islet function and
insulin sensitivity may provide one explanation. Similarly, the
emergence of glucose intolerance with age in Vps13cKO
mice, which is reminiscent of changes seen after the inactiva-
tion of the T2D GWAS gene Tcf7l2 in mice (43, 82), seems to
reflect, at least in part, increasing insulin resistance as well as
impaired insulin output from the pancreas. Of note, recent
studies report relatively preserved glucose sensing of isolated
islets with age in both mice and humans (3, 26) but suggest a
role for altered vascularization and fibrosis in impaired insulin
secretion in vivo (3).
Strikingly, the impairments in glucose tolerance apparent in
both male and female Vps13cKO mice vs. littermate controls
at this age were abolished after maintenance on HFD. These
findings demonstrate an interesting interaction between the
inheritance of a genetic factor influencing risk, and age [as
observed in human T2D, (87)] as well as sex and diet. The
reasons for the difference in penetrance between the effects of
Vps13c deletion observed here between male and female mice
remain unknown but may reflect interactions with sex hor-
mones at the level of the individual -cell (46) or, alternatively,
subtle differences in insulin sensitivity between the sexes that
go on to influence the effect of perturbations in the -cell on
overall glucose homeostasis.
Examined in either males or females, -cell mass was not
different between control and knockout mice, indicating a
possible defect in -cell function as underlying the glucose
dyshomeostasis reported above. Correspondingly, clear ten-
dencies were apparent toward impaired -cell function and
lowered insulin levels when one combined fasting glycemia
with corresponding insulin plasma concentration using
HOMA2 analysis (particularly in females; Fig. 7, E and G).
According to this analysis, insulin sensitivity was slightly but
significantly increased in knockout females vs. littermate con-
trols (Fig. 7H), again indicating that a defect in -cell function
is likely to underlie the mild glucose intolerance in knockout
mice (and subject to caveats in extrapolating HOMA2 models
from humans to rodents) (74).
On the other hand, we were unable to detect any impairment
in glucose or depolarization-induced insulin secretion as as-
sessed ex vivo in isolated islets (Fig. 8). Indeed, in islets
isolated from animals maintained on either RC or HFD, we
observed a tendency in male Vps13cKO mice toward en-
hanced insulin secretion in response to either high glucose or
KCl and in female Vps13cKO in response to high glucose.
By contrast, stimulated insulin secretion in response to KCl
tended not to change in Vps13cKO vs. control islets from
females fed RC or HFD. We are therefore unable at the present
time to assign the changes in -cell function and glucose
homeostasis observed in vivo unambiguously to alterations in
islet responses measureable in vitro. We would stress, how-
ever, that the mechanisms responsible for the stimulation of
insulin secretion by elevated glucose in vivo, which are likely
to be modulated by a multitude of humoral (e.g., circulating
fatty acids, incretins, adipokines, etc.), neuronal (56), and other
inputs into the islet, are unlikely to match perfectly those tested
in vitro.
Nonetheless, detailed analysis of glucose- and KCl-induced
Ca2 dynamics did provide evidence for alterations at the level
of secretory granule behavior, which may play a role to impair
insulin secretion in vivo. Importantly, islets from male
Vps13cKO mice maintained on RC or on HFD responded
normally with insulin secretion in response to either glucose or
high KCl (Fig. 8), consistent with mild, and late-onset, glucose
intolerance in these animals. Glucose-induced Ca2 increases
were nonetheless significantly delayed in the KO animals (Fig.
10). By contrast, when fed on RC, islets from female
Vps13cKO mice displayed a significant enhancement in glu-
cose-stimulated Ca2 increases vs. islets from control litter-
mates (Fig. 11A), whereas GSIS was unaltered (and tended to
be decreased in response to KCl), as mentioned above. These
observations suggest that the Ca2 responsiveness of the se-
cretory machinery to intracellular Ca2 increases may be
diminished in female Vps13cKO mice, perhaps reflecting
changes in the number of fusion-competent secretory granules,
as reported after manipulation of the GWAS gene TCF7L2
(81) or the microRNA miR124 (4) and might suggest a com-
mon mode of action of genes affecting T2D risk. Finally, it is
possible, given that proinsulin levels were elevated in carriers
of risk alleles, that prohormone processing is altered after
Vps13c inactivation (67). To investigate this hypothesis, we
measured random-fed insulin and proinsulin concentrations in
RC-fed mice. No differences were seen in either insulin or
proinsulin plasma concentrations, nor was the insulin/proinsu-
lin ratio different between controls and KO mice (Fig. 13).
Changes in glucose tolerance were not apparent after the
maintenance of mice (either male of female) on a HFD,
Fig. 11. Effect of Vps13c deletion on calcium signaling in vitro in female mouse islets. Isolated islets from female mice (20–23 wk of age) maintained on RC
(A) or HFD (B) were loaded with Fluo 2 and analyzed as for male islets (Fig. 10). (i), mean free calcium (F/F0); (ii), inset from (i), mean free calcium measured
between 300 and 500 s, showing stimulation with 16.7 mM glucose; (iii), AUC analysis for high glucose stimulation; (iv), AUC analysis for KCl stimulation;
(v), time to maximum peak value from stimulation with glucose; (vi), maximum peak value (F/F0) from stimulation with glucose; (vii), time to maximum peak
value from stimulation with KCl; (viii), maximum peak value (F/F0) from stimulation with KCl; n  3–5 mice per genotype. Number of islets used: female RC,
n  47–48 islets from 4 mice; female HFD, n  46–59 islets from 4 or 5 mice (KO vs. Ctrl, respectively). *P  0.5; **P  0.01; ***P  0.001; unpaired
Student’s t-test.
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suggesting that the phenotype might be rescued by changes in
response to high-fat feeding and insulin resistance. One possi-
ble explanation might be an increase in the expression of other
VPS13 family members, which could be triggered by a HFD,
thus compensating for the absence of VPS13C. According to a
recent study of mouse islet cell transcriptomes (5), Vps13c
mRNA levels are two to three times those of Vps13a, -b, and
-d in the -cell under conditions of normal feeding. Whether
changes in the expression of any of these genes occur under the
stress of a HFD has yet to be investigated. We note also that a
recent eQTL study (9) did not report a significant association
with VPS13C (or other genes at this locus) and T2D risk,
INSULIN VPS13C Merge
Fig. 12. Subcellular localization of VPS13C in human -cells. Immunocytochemical analysis for insulin (green) and VPS13C (red) was performed using confocal
microscopy in single -cells as described in MATERIALS AND METHODS. Scale bar, 10 m.
Fig. 13. Random-fed insulin and proinsulin plasma concen-
trations in RC-fed mice. Plasma insulin and proinsulin were
measured following collection from the tail vein (before
culling) and aorta (immediately post mortem) of RC-fed
Ctrl (black) or KO [green, males (A and B); purple, females
(C and D)] mice aged over 21 wk. The ratio plasma
insulin/plasma proinsulin is shown in E; n  7 Ctrl and 8
KO (males), 10 Ctrl and 9 KO (females).
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although whether the latter study was adequately powered to
detect small changes is uncertain.
How might VPS13C influence insulin secretion in vivo?
Clues might be gleaned by comparisons with other members of
the VPS13 family. BLAST analysis of the protein sequences of
the four family members indicates that VPS13C is most similar
to VPS13A, sharing 41% identity (73) and the two proteins
possess several common domains and have similar NH2 and
COOH termini, indicating that they may have similar functions
(73). Both can attach to membranes, although VPS13C has
intramolecular duplications vs. VPS13A, which may imply
neofunctionalization (i.e., the acquiring of new roles) com-
pared with VPS13A (73). As noted above, a loss of VPS13A
(also called chorein) expression leads to the rare neurodegen-
erative disease chorea-acanthocytosis (ChAc) (53, 71). Symp-
toms include cognitive dysfunction, hyperkinetic movement
disorder, and erythrocyte acanthocytosis (72), leading to sig-
nificant disability and a reduced life expectancy. Since the
discovery of the cause of ChAc, much work has been done to
investigate the molecular function of VPS13A. The protein has
been localized to endosomal structures in yeast and erythro-
cytes (14, 28, 64, 70) as well as to the Golgi, and cofractionates
with dense-core vesicles in synaptosomes (25, 34). VPS13A is
also implicated in a plethora of cellular processes in different
settings, including regulation of the actin cytoskeleton (2, 18,
64), protein trafficking (7), membrane morphogenesis (48),
autophagy (45), and phagocytosis (59). Cells depleted of
VPS13A have decreased levels of PI(4)P and of phosphory-
lated PI3K (18, 47, 48). Importantly, further evidence for a role
for VPS13A in the control of regulated exocytosis was pro-
vided recently by Hayashi et al. (25), who demonstrated that
VPS13A is localized to neurites in dopaminergic PC12 cells.
These findings are thus strongly reminiscent of our findings
here of colocalization between VPS13C and insulin in human
-cells (Fig. 12). The role for VPS13A in phosphoinositide
(PI) metabolism is a function that is conserved between yeast
and human orthologs and a possible mechanism by which
VPS13A can function in so many different cellular processes
(18, 47–49). If VPS13C were to have similar functions in
-cells as VPS13A, we would hypothesize that the former
might be involved in protein trafficking, potentially through the
regulation of PI metabolism.
Correct regulation of PI metabolism is essential for efficient
insulin secretion from -cells (79). Indeed, PI(4)P is the main
precursor to form PI(4,5)P2, which is rapidly turned over to
form second messengers required for insulin secretion (68) in
a Ca2-dependent manner akin to the release of neurotrans-
mitters from neurons. Interestingly, a distinct role for PI(4)P in
signaling from the plasma membrane in the -cell has been
suggested (80), since PI(4)P displayed antisynchronous oscil-
lations compared with PI(4,5)P2 when MIN6 -cells were
stimulated with glucose. A direct role in secretion has already
been shown in yeast (24), and it is well known that PI(4)P is
involved in membrane trafficking between the Golgi and the
plasma membrane and other endosomal compartments (75).
Hence, VPS13C could function in insulin secretion through
regulation of PI metabolism, affecting intracellular insulin
trafficking.
Interestingly, new work shows that VPS13C is involved in
lipid droplet formation and regulation of galectin-12 and seems
to function in adipogenesis (84). The latter findings indicate
that VPS13C may play additional roles in T2D in extra-
pancreatic tissues.
In conclusion, human islet expression data suggest that
variations in the level of expression of VPS13C and C2CD4A
in the -cell may contribute to altered T2D susceptibility in
risk allele carriers, at least in females. The relatively mild
effects of Vps13c ablation on glucose homeostasis are consis-
tent with the hypothesis that changes in the expression of both
genes may contribute to overall risk. Future functional studies
will be required to determine the role of C2CD4A in the
control of insulin secretion and the possible contribution of
indirect mechanisms resulting from changes in the expression
of either gene in extrapancreatic tissues.
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